Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Inflammatory Biomarkers
100%
Stage III Colon Cancer
100%
Interleukin-6
50%
Inflammation
50%
High-sensitivity C-reactive Protein (hs-CRP)
50%
Disease-free Survival
50%
Soluble Tumor Necrosis Factor Receptor 2
50%
Overall Survival
33%
After Surgery
33%
Recurrence-free Survival
33%
Plasma Samples
33%
Cox Proportional Hazards Regression
16%
Hazard Ratio
16%
Chemotherapy
16%
Trial Registration
16%
Adjusted Hazard Ratio
16%
Cancer Mortality
16%
Chronic Inflammation
16%
Leukemia
16%
National Cancer Institute
16%
Colon Cancer
16%
Adjuvant Chemotherapy
16%
Cancer Outcomes
16%
Recurrence Risk
16%
Survival Outcomes
16%
Risk of Death
16%
Plasma Concentration
16%
Biomarker Testing
16%
Celecoxib
16%
Southwest Oncology Group
16%
Colorectal Cancer Death
16%
Colon Cancer Recurrence
16%
Colorectal Cancer Recurrence
16%
Patient Median
16%
Anti-inflammatory Intervention
16%
Nursing and Health Professions
Biological Marker
100%
Colon Carcinoma
100%
C Reactive Protein
50%
Inflammation
50%
Interleukin 6
50%
Disease Free Survival
50%
Tumor Necrosis Factor Receptor 2
50%
Overall Survival
33%
Cohort Analysis
33%
Hazard Ratio
33%
Recurrent Disease
33%
Cancer Mortality
33%
Recurrence Free Survival
33%
Randomization
33%
Cancer Recurrence
33%
Proportional Hazards Model
16%
Malignant Neoplasm
16%
Chronic Inflammation
16%
National Health Organization
16%
Blood Level
16%
Adjuvant Chemotherapy
16%
Leukemia
16%
Celecoxib
16%
Colorectal Carcinoma
16%
Chemotherapy
16%
Antiinflammatory
16%
Medicine and Dentistry
Biological Marker
100%
Colon Carcinoma
100%
C Reactive Protein
50%
Interleukin 6
50%
Disease Free Survival
50%
Tumor Necrosis Factor Receptor 2
50%
Inflammation
50%
Malignant Neoplasm
33%
Hazard Ratio
33%
Overall Survival
33%
Cancer Mortality
33%
Cohort Analysis
33%
Recurrent Disease
33%
Cancer Recurrence
33%
Recurrence Free Survival
33%
Proportional Hazards Model
16%
Chronic Inflammation
16%
Oncology
16%
Adjuvant Chemotherapy
16%
Anti-Inflammatory Drug
16%
Leukemia
16%
Celecoxib
16%
Colorectal Carcinoma
16%
Chemotherapy
16%
Median Follow Up
16%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Colon Carcinoma
100%
Inflammation
50%
Disease Free Survival
50%
C Reactive Protein
50%
Interleukin 6
50%
Tumor Necrosis Factor Receptor 2
50%
Cohort Study
33%
Malignant Neoplasm
33%
Cancer Mortality
33%
Overall Survival
33%
Recurrent Disease
33%
Cancer Recurrence
33%
Chemotherapy Regimens
33%
Recurrence Free Survival
33%
Leukemia
16%
Chronic Inflammation
16%
Anti-Inflammatory Drug
16%
Celecoxib
16%
Colorectal Carcinoma
16%
Immunology and Microbiology
Colon
100%
Inflammation
80%
Blood Plasma
60%
Disease Free Survival
60%
Interleukin 6
60%
C-Reactive Protein
60%
Tumor Necrosis Factor Receptor 2
60%
Overall Survival
40%
Recurrence Free Survival
40%
Blood Level
20%
Colorectal Carcinoma
20%
Mathematics
IQR
100%
Median
50%
Hazard Ratio
33%
Randomization
33%
Proportional Hazards Model
16%
Median Age
16%
Proportional Hazard Regression
16%